Drug Profile
Tepoditamab - Merus
Alternative Names: CLEC12A x CD3 Biclonics®; MCLA-117Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Merus
- Developer Institute Gustave-Roussy; LGC; Merus; Pharmaceutical Research Associates; VU University Medical Center
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy, In the elderly) in Belgium (Parenteral)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy, In the elderly) in France (Parenteral)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy, In the elderly) in Italy (Parenteral)